SCHEMBL4771450

SCHEMBL4771450

c1ccc(-c2nc(NCCc3nc(-c4cccnc4)no3)cc(-c3cccnc3)n2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.52
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 5/20 0.51
TSHR P16473 4/20 0.51
TP53 P04637 1/20 0.51
PKM P14618 1/20 0.51
MAPK1 P28482 4/20 0.50
KMT2A Q03164 2/20 0.48
HTT P42858 1/20 0.48
PPARA Q07869 1/20 0.48
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC8 Q9BY41 1/20 0.47
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240945 0.83 GBA1 (0.54) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL2238098 0.83 PTGDR (0.53) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL2237295 0.82 CYP2A6 (0.45) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL4765953 0.82 LMNA (0.52) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL2237320 0.81 HIF1A (0.47) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL2243750 0.80 PTGDR (0.41) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL2242475 0.80 PTGDR (0.54) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL2238047 0.79 KDM6B (0.41) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL4775234 0.79 LMNA (0.49) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL2243751 0.78 PTGDR (0.44) NPC1RAB9ASMN1; SMN2TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed